Datopotamab Deruxtecan, often abbreviated as DATO, represents the notable advancement regarding targeted cancer treatment. This novel antibody-drug conjugate joins the monoclonal antigen specifically focused on HER2 https://prbookmarkingwebsites.com/story28218293/datopotamab-deruxtecan-the-promising-antibody-drug-conjugate